Ahan, Recep E.Hanifehnezhad, AlirezaKehribar, Ebru S.Oguzoglu, Tuba C.Foldes, KatalinOzcelik, Cemile E.Filazi, NazlicanOztop, SidikaPalaz, FahreddinOnder, SevgenBozkurt, Eray U.Ergunay, KorayOzkul, AykutSeker, Urartu Ozgur Safak2023-01-092023-01-0920222373-8227https://pubs.acs.org/doi/pdf/10.1021/acsinfecdis.2c00006http://hdl.handle.net/11727/8567The COVID-19 (coronavirus disease-19) pandemic affected more than 180 million people around the globe, causing more than five million deaths as of January 2022. SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), the new coronavirus, has been identified as the primary cause of the infection. The number of vaccinated people is increasing; however, prophylactic drugs are highly demanded to ensure secure social contact. A number of drug molecules have been repurposed to fight against SARS-CoV-2, and some of them have been proven to be effective in preventing hospitalization or ICU admissions. Here, we demonstrated griffithsin (GRFT), a lectin protein, to block the entry of SARS-CoV-2 and its variants, Delta and Omicron, into the Vero E6 cell lines and IFNAR(-/-) mouse models by attaching to the spike protein of SARS-CoV-2. Given the current mutation frequency of SARS-CoV-2, we believe that GRFT protein-based drugs will have a high impact in preventing the transmission of both the Wuhan strain as well as any other emerging variants, including Delta and Omicron variants, causing the high-speed spread of COVID-19.enginfo:eu-repo/semantics/openAccessGRIFFITHSINCORONAVIRUSPNEUMONIAarticle87125312640008825948000012-s2.0-85128815159